symbicort turbuhaler 4.5mcg + 160mcg prašak za inhalaciju
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - formoterol, budesonid - prašak za inhalaciju - 4.5mcg + 160mcg
airbufo forspiro 4.5mcg/doza + 160mcg/doza prašak za inhalaciju, podijeljen
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - formoterol, budesonid - prašak za inhalaciju, podijeljen - 4.5mcg/doza + 160mcg/doza
duoresp spiromax 4.5mcg + 160mcg prašak za inhalaciju
"evropa lek pharma" doo podgorica - formoterol, budesonid - prašak za inhalaciju - 4.5mcg + 160mcg
duoresp spiromax 9mcg + 320mcg prašak za inhalaciju
"evropa lek pharma" doo podgorica - formoterol, budesonid - prašak za inhalaciju - 9mcg + 320mcg
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lijekovi za opstruktivne plućne bolesti dišnih putova, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
vylaer spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lijekovi za opstruktivne plućne bolesti dišnih putova, - vylaer spiromax je indiciran u odrasloj dobi od 18 i više godina. asthmavylaer spiromax drugačije u redovnom liječenju astme, gdje je upotreba kombinacije (inhalacijskim kortikosteroidima i trajno djeluju β2 адренорецепторов) prikladno:u bolesnika adekvatno ne prati ингаляционными kortikosteroidima i "po potrebi" udahnuti короткодействующих β2 адреномиметиков. Орин pacijenata već adekvatno prati na oba inhalacijskim kortikosteroidima i trajno djeluju β2 адреномиметиков. copdsymptomatic liječenje bolesnika s teškim kopb (ОФВ1 < 50%, predviđa normalno) i ponovljenim vrhunac, koji imaju značajne simptome, unatoč regularnu terapiju s длинн-djeluje bronhodilatatora.
airbufo forspiro 160 µg/1 doza+ 4,5 µg/1 doza prašak za inhalaciju, podijeljeni
sandoz d.o.o. - будесонид, formoterol - prašak za inhalaciju, podijeljeni - 160 µg/1 doza+ 4,5 µg/1 doza - 1 isporučena doza sadrži: 160 µg budesonida 4,5 µg formoterol fumarat dihidrata
airbufo forspiro 160 µg/1 doza+ 4,5 µg/1 doza prašak za inhalaciju, podijeljeni
sandoz d.o.o. - будесонид, formoterol - prašak za inhalaciju, podijeljeni - 160 µg/1 doza+ 4,5 µg/1 doza - 1 isporučena doza sadrži: 160 µg budesonida 4,5 µg formoterol fumarat dihidrata
duoresp spiromax 160 µg/1 doza+ 4.5 µg/1 doza prašak inhalata
pliva d.o.o.sarajevo - будесонид, formoterol - prašak inhalata - 160 µg/1 doza+ 4.5 µg/1 doza - 1 doza sadrži: 160 mikrograma budesonida 4,5 mikrograma formoterol fumarat dihidrata
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - lijekovi za opstruktivne plućne bolesti dišnih putova, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).